Adsorció de crom (VI) i crom (III) en solució amb closca de cranc

En l’eliminació del crom en suspensió de les aigües residuals de les indústries es realitzen dos processos: una precipitació en medi àcid on es redueix el crom (VI) a crom (III) en què s’elimina la major part del crom, i el següent tractament es fa per bescanvi iònic o per adsorció. Els adsorbents emprats actualment tenen un elevat cost i s’està estudiant nous adsorbents, com a substituts dels tradicionals, de baix cost. Dins d’aquest adsorbents de baix cost es troben els bioadsorbents, biomaterials amb gran capacitat d’adsorció. L’objectiu del projecte es va centrar en l’estudi de l’adsorció de crom trivalent i hexavalent en solucions aquoses utilitzant com a adsorbent el residu industrial de closca de cranc, provinent d’una indústria alimentària de barretes de cranc

Convenient synthesis of heterobifunctional poly(ethylene glycol) suitable for the functionalization of iron oxide nanoparticles for biomedical applications.

A straightforward route is proposed for the multi-gram scale synthesis of heterobifunctional poly(ethylene glycol) (PEG) oligomers containing combination of triethyloxysilane extremity for surface modification of metal oxides and amino or azido active end groups for further functionalization. The suitability of these PEG derivatives to be conjugated to nanomaterials was shown by pegylation of ultrasmall superparamagnetic iron oxide (USPIO) nanoparticles (NPs), followed by functionalization with small peptide ligands for biomedical applications.

Perioperative intravenous iron; an upfront therapy for treating anaemia and reducing transfusion requirements.

Perioperative anaemia, with iron deficiency being its leading cause, is a frequent condition among surgical patients, and has been linked to increased postoperative morbidity and mortality, and decreased quality of life. Postoperative anaemia is even more frequent and is mainly caused by perioperative blood loss, aggravated by inflammation-induced blunting of erythropoiesis. Allogenic transfusion is commonly used for treating acute perioperative anaemia, but it also increases the rate of morbidity and mortality in surgical and critically ill patients. Thus, overall concerns about adverse effects of both preoperative anaemia and allogeneic transfusion have prompted the review of transfusion practice and the search for safer and more biologically rational treatment options. In this paper, the role of intravenous iron therapy (mostly with iron sucrose and ferric carboxymaltose), as a safe and efficacious tool for treating anaemia and reducing transfusion requirements in surgical patients, as well as in other medical areas, has been reviewed. From the analysis of published data and despite the lack of high quality evidence in some areas, it seems fair to conclude that perioperative intravenous iron administration, with or without erythropoiesis stimulating agents, is safe, results in lower transfusion requirements and hastens recovery from postoperative anaemia. In addition, some studies have reported decreased rates of postoperative infection and mortality, and shorter length of hospital stay in surgical patients receiving intravenous iron.

Biblia sacra, pars. III

Evangeliorum canones (4v) ; Evang. Matthaei (13v), Marci (33v), Lucae (47v), Johannis (68v) ; XIV Epist. Pauli (88) ; Actus Apost. (139v) ; VII Epist. canon. (161) ; Apocalypsis (172v).

ordo Romanae Ecclesiae curiaeque, qui obtinuit à temporibus Innocentii Papae III. ad Clementem V.

Colbertinus

Prevalence and Clinical Outcomes for Patients With ALK-Positive Resected Stage I to III Adenocarcinoma: Results From the European Thoracic Oncology Platform Lungscape Project.

PURPOSE: The prevalence of anaplastic lymphoma kinase (ALK) gene fusion (ALK positivity) in early-stage non-small-cell lung cancer (NSCLC) varies by population examined and detection method used. The Lungscape ALK project was designed to address the prevalence and prognostic impact of ALK positivity in resected lung adenocarcinoma in a primarily European population. METHODS: Analysis of ALK status was performed by immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH) in tissue sections of 1,281 patients with adenocarcinoma in the European Thoracic Oncology Platform Lungscape iBiobank. Positive patients were matched with negative patients in a 1:2 ratio, both for IHC and for FISH testing. Testing was performed in 16 participating centers, using the same protocol after passing external quality assessment. RESULTS: Positive ALK IHC staining was present in 80 patients (prevalence of 6.2%; 95% CI, 4.9% to 7.6%). Of these, 28 patients were ALK FISH positive, corresponding to a lower bound for the prevalence of FISH positivity of 2.2%. FISH specificity was 100%, and FISH sensitivity was 35.0% (95% CI, 24.7% to 46.5%), with a sensitivity value of 81.3% (95% CI, 63.6% to 92.8%) for IHC 2+/3+ patients. The hazard of death for FISH-positive patients was lower than for IHC-negative patients (P = .022). Multivariable models, adjusted for patient, tumor, and treatment characteristics, and matched cohort analysis confirmed that ALK FISH positivity is a predictor for better overall survival (OS). CONCLUSION: In this large cohort of surgically resected lung adenocarcinomas, the prevalence of ALK positivity was 6.2% using IHC and at least 2.2% using FISH. A screening strategy based on IHC or H-score could be envisaged. ALK positivity (by either IHC or FISH) was related to better OS.

1.° Anonymi tractatus de algorismo, sive de arte numerandi : praemittuntur tractatus de numerorum mysteriis, et narratio Fratris Benedicti Aretini de indulgentia loco de Portiuncula concessa ab Honorio Papa III. — 2.° Magistri Joannis de Sacrobosco tractatus de computo. — 3.° Ejusdem tractatus de sphaera. — 4.° Theorica planetarum : authore Gerardo Carmonensi. — 5.° Anonymi explicationes allegoricae quorumdam Scripturae sacrae locorum : initium desideratur. — 6.° Elementorum Euclidis libri quinque priores. — 7.° Anonymi tractatus de speculis.

Colbertinus

Aprendiendo entre iguales, lema del III encuentro Forma Joven

Boletín semanal para profesionales sanitarios de la Secretaría General de Salud Pública y Participación Social de la Consejería de Salud